Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
643 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01471210 | Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 124 | Bristol-Myers SquibbINDUSTRY | 4 | Apr 19, 2017 | clinicaltrials |
| NCT02110082 | Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer | completed | Phase 1 | 66 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 19, 2017 |
| clinicaltrials |
| NCT01632150 | Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma | completed | Phase 2 | 51 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 14, 2017 | clinicaltrials |
| NCT01775631 | Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma | completed | Phase 1 | 47 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 31, 2017 | clinicaltrials |
| NCT01357655 | Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923) | terminated | Phase 2 | 70 | Bristol-Myers SquibbINDUSTRY | 8 | Mar 14, 2017 | clinicaltrials |
| NCT00560352 | Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma | terminated | Phase 1 | 16 | Bristol-Myers SquibbINDUSTRY | 4 | Mar 13, 2017 | clinicaltrials |
| NCT00481247 | A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia(DASISION) | completed | Phase 3 | 547 | Bristol-Myers SquibbINDUSTRY | 27 | Feb 15, 2017 | clinicaltrials |
| NCT02186249 | Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma(CheckMate218) | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 2 | Feb 8, 2017 | clinicaltrials |
| NCT02536469 | HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors | completed | Phase 1 | 15 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01660906 | Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib | completed | Phase 4 | 39 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 22, 2016 | clinicaltrials |
| NCT00744497 | Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer(READY) | completed | Phase 3 | 1,930 | Bristol-Myers SquibbINDUSTRY | 25 | Oct 17, 2016 | clinicaltrials |
| NCT00858871 | First Line Hepato Cellular Carcinoma (HCC)(BRISK FL) | completed | Phase 3 | 1,714 | Bristol-Myers SquibbINDUSTRY | 26 | Oct 17, 2016 | clinicaltrials |
| NCT00362713 | Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection | completed | Phase 1 | 12 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 30, 2016 | clinicaltrials |
| NCT00420186 | A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin | completed | Phase 1 | 37 | Bristol-Myers SquibbINDUSTRY | 3 | Sep 30, 2016 | clinicaltrials |
| NCT00861614 | Study of Immunotherapy to Treat Advanced Prostate Cancer | completed | Phase 3 | 988 | Bristol-Myers SquibbINDUSTRY | 27 | Sep 30, 2016 | clinicaltrials |
| NCT00884546 | Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma | completed | Phase 1 | 27 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 30, 2016 | clinicaltrials |
| NCT01188278 | Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey | completed | — | 173 | Bristol-Myers SquibbINDUSTRY | 0 | Sep 30, 2016 | clinicaltrials |
| NCT00261365 | Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010) | completed | Phase 1 / Phase 2 | 80 | Bristol-Myers SquibbINDUSTRY | 7 | Sep 29, 2016 | clinicaltrials |
| NCT02142218 | Expanded Access Program With Nivolumab to Treat Melanoma(Checkmate 168) | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 6 | Sep 29, 2016 | clinicaltrials |
| NCT00135408 | A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide | completed | Phase 2 | 115 | Bristol-Myers SquibbINDUSTRY | 6 | Sep 28, 2016 | clinicaltrials |
| NCT00289627 | A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma | completed | Phase 2 | 155 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 28, 2016 | clinicaltrials |
| NCT00035152 | Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer | completed | Phase 3 | 444 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 19, 2016 | clinicaltrials |
| NCT00362830 | A Study of the Alternative Administration of Ixabepilone and Vinflunine | completed | Phase 1 | 60 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 19, 2016 | clinicaltrials |
| NCT00388557 | Effect of Ketoconazole on the Pharmacokinetics of Vinflunine | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 19, 2016 | clinicaltrials |
| NCT01986218 | Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 36 | Bristol-Myers SquibbINDUSTRY | 3 | Sep 15, 2016 | clinicaltrials |
| NCT00123474 | Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML | completed | Phase 3 | 724 | Bristol-Myers SquibbINDUSTRY | 31 | Aug 25, 2016 | clinicaltrials |
| NCT01057810 | Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | completed | Phase 3 | 837 | Bristol-Myers SquibbINDUSTRY | 24 | Aug 18, 2016 | clinicaltrials |
| NCT00320255 | A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer | completed | Phase 2 | 130 | Bristol-Myers SquibbINDUSTRY | 2 | Aug 16, 2016 | clinicaltrials |
| NCT00560391 | Dasatinib in Combination With Revlimid (and Dexamethasone) | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 3 | Aug 4, 2016 | clinicaltrials |
| NCT00162123 | A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies | completed | Phase 2 | 248 | Bristol-Myers SquibbINDUSTRY | 18 | Jul 27, 2016 | clinicaltrials |
| NCT01394666 | Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML) | completed | — | 150 | Bristol-Myers SquibbINDUSTRY | 0 | Jul 11, 2016 | clinicaltrials |
| NCT01086267 | Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 17 | Bristol-Myers SquibbINDUSTRY | 2 | Jun 27, 2016 | clinicaltrials |
| NCT01218477 | Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) | completed | Phase 1 / Phase 2 | 33 | Bristol-Myers SquibbINDUSTRY | 7 | Jun 17, 2016 | clinicaltrials |
| NCT02794636 | Interferon Toxicities in Melanoma Treatment(ITMT) | completed | — | 436 | Bristol-Myers SquibbINDUSTRY | 0 | Jun 9, 2016 | clinicaltrials |
| NCT00754325 | Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor | completed | Phase 2 | 100 | Bristol-Myers SquibbINDUSTRY | 1 | May 26, 2016 | clinicaltrials |
| NCT00651508 | Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 1 | Bristol-Myers SquibbINDUSTRY | 1 | May 17, 2016 | clinicaltrials |
| NCT01585987 | An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy | completed | Phase 2 | 143 | Bristol-Myers SquibbINDUSTRY | 12 | May 17, 2016 | clinicaltrials |
| NCT01482728 | Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer | completed | Early Phase 1 | 12 | University of VirginiaOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT01464047 | Korean Post-marketing Surveillance for Sprycel® | completed | — | 670 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 27, 2016 | clinicaltrials |
| NCT02733445 | Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib | completed | — | 2,650 | Bristol-Myers SquibbINDUSTRY | 0 | Apr 11, 2016 | clinicaltrials |
| NCT01359657 | Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 46 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 16, 2016 | clinicaltrials |
| NCT01990859 | Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients | completed | Phase 2 | 20 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 14, 2016 | clinicaltrials |
| NCT00455533 | Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer | completed | Phase 2 | 384 | Bristol-Myers SquibbINDUSTRY | 15 | Feb 24, 2016 | clinicaltrials |
| NCT00324077 | Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | withdrawn | Phase 2 / Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 17, 2016 | clinicaltrials |
| NCT00732186 | Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00982488 | Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia(START rollover) | completed | Phase 2 | 238 | Bristol-Myers SquibbINDUSTRY | 24 | Jan 22, 2016 | clinicaltrials |
| NCT02224768 | YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey | completed | — | 158 | Bristol-Myers SquibbINDUSTRY | 2 | Dec 21, 2015 | clinicaltrials |
| NCT00389155 | First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | completed | Phase 2 / Phase 3 | 34 | Bristol-Myers SquibbINDUSTRY | 16 | Dec 7, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials